PDSB vs PHGE

PDS Biotechnology Corporation vs BiomX Inc. — Valuation Comparison 2026

PDSB

Biotechnology
PDS Biotechnology Corporation
Quality
4.0
out of 10
Value Trap
30
LOW
Price
$1.07
Last close
Models
7/13
Active
VS

PHGE

Biotechnology
BiomX Inc.
Quality
3.3
out of 10
Value Trap
44
WARN
Price
$1.56
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType PDSB Fair ValuePDSB Upside PHGE Fair ValuePHGE Upside
Bayesian DCF Intrinsic $0.50 -53.6% $0.48 -56.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.63 -40.9% $2.32 +49.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PDSB vs PHGE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PDSB vs PHGE — Which Stock Is More Undervalued?

PDSB scores higher with a 4.0/10 quality rating vs PHGE's 3.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing PDS Biotechnology Corporation (PDSB) and BiomX Inc. (PHGE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PDSB currently trades at $1.07 with a QOC of 4.0/10, while PHGE trades at $1.56 with a QOC of 3.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).